| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
VVY Stock Overview
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer’s disease.
Vivoryon Therapeutics N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €8.58 |
| 52 Week High | €22.58 |
| 52 Week Low | €6.82 |
| Beta | 1.99 |
| 1 Month Change | 22.92% |
| 3 Month Change | -1.15% |
| 1 Year Change | -57.02% |
| 3 Year Change | 31.60% |
| 5 Year Change | -42.80% |
| Change since IPO | -57.10% |
Recent News & Updates
Shareholder Returns
| VVY | NL Biotechs | NL Market | |
|---|---|---|---|
| 7D | 7.2% | 2.3% | 2.9% |
| 1Y | -57.0% | -14.1% | -13.4% |
Return vs Industry: VVY underperformed the Dutch Biotechs industry which returned -13.1% over the past year.
Return vs Market: VVY underperformed the Dutch Market which returned -13.7% over the past year.
Price Volatility
| VVY volatility | |
|---|---|
| VVY Average Weekly Movement | 10.3% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in NL Market | 8.0% |
| 10% least volatile stocks in NL Market | 2.9% |
Stable Share Price: VVY is more volatile than 90% of Dutch stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: VVY's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Dutch stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 15 | Ulrich Dauer | https://www.vivoryon.com |
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer’s disease. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease; and for the treatment of cancer.
Vivoryon Therapeutics N.V. Fundamentals Summary
| VVY fundamental statistics | |
|---|---|
| Market Cap | €189.19m |
| Earnings (TTM) | -€12.65m |
| Revenue (TTM) | €10.76m |
17.6x
P/S Ratio-15.0x
P/E RatioIs VVY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VVY income statement (TTM) | |
|---|---|
| Revenue | €10.76m |
| Cost of Revenue | €1.57m |
| Gross Profit | €9.20m |
| Other Expenses | €21.85m |
| Earnings | -€12.65m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.57 |
| Gross Margin | 85.42% |
| Net Profit Margin | -117.57% |
| Debt/Equity Ratio | 0% |
How did VVY perform over the long term?
See historical performance and comparison